European Commission Approves Maintenance Rucaparib in Ovarian Cancer

January 24, 2019 – The European Commission has approved an expanded indication for single-agent rucaparib as a maintenance therapy in adult patients with platinum-sensitive, relapsed, high-grade, epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to platinum-based chemotherapy, regardless of BRCA status. The approval is based on results from the phase III ARIEL3 trial, in which rucaparib led to an … (leggi tutto)